Why the study?
Does immunoglobulin treatment improve cardiac function and systemic inflammation in a patient with fulminant myocarditis?
Does immunoglobulin treatment improve cardiac function and systemic inflammation in a patient with fulminant myocarditis?
Immunoglobulin treatment may improve cardiac function in fulminant myocarditis, and serum thioredoxin could serve as a biomarker for disease activity.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for IVIG in fulminant myocarditis; leaves open thioredoxin as disease activity biomarker.
A 31-year-old woman suspected to have acute myocarditis was admitted to hospital and was managed with intra-aortic balloon pumping and a percutaneous cardiopulmonary support system because of sustained ventricular tachycardia. After immunoglobulin treatment, cardiac function and systematic inflammation were improved. The left ventricular endomyocardial biopsy revealed massive necrosis and degeneration of myocardial cells, and extensive infiltration of inflammatory cells. The clinicopathology of this patient was thought to be fulminant myocarditis. Serial serum thioredoxin (TRX) analysis showed that the serum level was high during the acute phase, and decreased during the chronic phase. Immunohistochemistry for TRX in the biopsy samples showed that inflammatory cells and cardiomyocytes were positively stained.
No takes yet. Share an insight, caveat, or question.
Shioji et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: